Cooper Financial Group Acquires 1,236 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Cooper Financial Group boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 6.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,377 shares of the biotechnology company’s stock after acquiring an additional 1,236 shares during the quarter. Cooper Financial Group’s holdings in Exelixis were worth $712,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in EXEL. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Exelixis by 2.2% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 146,659 shares of the biotechnology company’s stock worth $4,884,000 after buying an additional 3,112 shares in the last quarter. Range Financial Group LLC bought a new stake in Exelixis in the fourth quarter valued at $994,000. Diversified Trust Co raised its stake in Exelixis by 4.7% during the fourth quarter. Diversified Trust Co now owns 20,136 shares of the biotechnology company’s stock worth $671,000 after acquiring an additional 902 shares in the last quarter. CWA Asset Management Group LLC lifted its holdings in shares of Exelixis by 22.4% during the fourth quarter. CWA Asset Management Group LLC now owns 27,201 shares of the biotechnology company’s stock valued at $906,000 after acquiring an additional 4,979 shares during the period. Finally, Nordea Investment Management AB boosted its stake in shares of Exelixis by 5.1% in the 4th quarter. Nordea Investment Management AB now owns 233,348 shares of the biotechnology company’s stock valued at $7,878,000 after purchasing an additional 11,331 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

EXEL has been the topic of several research analyst reports. Morgan Stanley upped their price objective on shares of Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, October 11th. Bank of America lowered Exelixis from a “buy” rating to a “neutral” rating and increased their price target for the stock from $35.00 to $39.00 in a research report on Tuesday, December 17th. Guggenheim lifted their price objective on Exelixis from $33.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. Piper Sandler increased their target price on Exelixis from $36.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Stifel Nicolaus lifted their price target on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.75.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Dana Aftab sold 1,162 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the sale, the executive vice president now directly owns 498,945 shares in the company, valued at approximately $15,666,873. This trade represents a 0.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jeffrey Hessekiel sold 25,000 shares of Exelixis stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $28.39, for a total transaction of $709,750.00. Following the completion of the transaction, the executive vice president now directly owns 580,325 shares in the company, valued at approximately $16,475,426.75. The trade was a 4.13 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 314,736 shares of company stock valued at $10,849,110. Corporate insiders own 2.85% of the company’s stock.

Exelixis Stock Down 2.0 %

Shares of Exelixis stock opened at $35.30 on Tuesday. Exelixis, Inc. has a 12 month low of $20.01 and a 12 month high of $36.97. The business has a fifty day simple moving average of $34.90 and a 200 day simple moving average of $28.99. The stock has a market cap of $10.08 billion, a PE ratio of 22.63, a price-to-earnings-growth ratio of 0.88 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million during the quarter, compared to analyst estimates of $490.31 million. During the same period in the previous year, the company earned $0.10 EPS. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. Analysts expect that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.